F
Forge Biologics
A gene therapy development engine, focused on enabling access to life changing gene therapies and helping bring them from idea into reality
About Forge Biologics
Forge Biologics is a biotechnology startup that specializes in the development and manufacturing of gene therapies. The company operates in the rapidly expanding gene therapy market, serving clients ranging from preclinical stage to commercial manufacturing. Their primary focus is on advancing gene therapy programs that aim to treat patients suffering from rare and devastating diseases.
The company's business model is centered around its proprietary "gene therapy development engine." This engine allows Forge Biologics to take innovative gene therapy concepts and bring them to reality, providing end-to-end manufacturing services. This means they handle everything from the initial development stages to the final production of the gene therapies.
Forge Biologics operates out of a custom-designed, 200,000+ square foot cGMP (Current Good Manufacturing Practice) facility, known as the Hearth. This facility allows them to manufacture AAV (Adeno-Associated Virus) gene therapies, a type of gene therapy that uses a virus to deliver genes into cells.
The company generates revenue by providing these manufacturing services to other companies and researchers in the gene therapy field. Additionally, they also develop their own innovative gene therapies, which could potentially provide additional revenue streams if these therapies are approved and commercialized.
In summary, Forge Biologics is a trailblazer in the gene therapy field, providing comprehensive manufacturing services and developing innovative therapies to treat genetic diseases.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2020
- Headquarters
- Columbus, United States
- Employees
- 438
- Open positions
- 15
- Dealroom signal
- 86.2/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Genetics and genomics, Spinout, Disease, Biotech and Pharma, Hard Tech, Woman Founder, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GROWTH EQUITY VCOther financing | May 2024 | $0 | — | Drive Capital | ↗ |
| ACQUISITIONOther financing | Nov 2023 | $620M | $620M | Ajinomoto | ↗ |
Growth signals
Latest recorded traffic for Forge Biologics is 6.4K monthly website visits, down 4.5% over the last three months. Forge Biologics's team grew 40.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Perceptive Advisors
Drive Capital
RA Capital Management
Citadel
Marshall Wace
Surveyor Capital
Octagon Capital Partners
Series B and later1 investor entered at this stage
Aisling Capital
Other known investors2 additional known investors
University of Pittsburgh
Ajinomoto
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Forge Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Forge Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.